23 November 2017
MorphoMed wins “Medtech Award” of aws Best of Biotech competition
Out of a total of 30 submitted projects, MorphoMed was awarded the Medtech prize by the Ministry of Science, Research and Economy in the 2017 Best of Biotech business plan competition organized by Austria Wirtschaftsservice GmbH (aws). MorphoMed had submitted its business plan regarding the development and commercialization of a new, regenerative anterior cruciate ligament implant from medical grade silk.
During the award ceremony in Palais Ferstl the representative of the Jury, Dr. Angelika Weinländer-Mölders explained that MorphoMed's business plan was awarded because of the evident medical need, the clear development strategy and the experienced management team that combines all necessary competences to realize the presented business plan.
LISA Vienna has donated the prize of 10,000.- Euro and the “Golden Viennese Heart”, a special trophy created for the Medtech award. The MorphoMed team had the pleasure to receive this trophy from Dr. Peter Halwachs, one of the managing directors of LISA Vienna.
“We are very happy about the decision of the Jury and the award” says Bernhard Küenburg, CEO of MorphoMed. “The Medtech award is a great motivation for the entire team to continue its efforts to develop this product, which is a perfect example for regenerative medicine”. Prof. Heinz Redl, head of MorphoMed's scientific board adds: “We feel very honored and it is also an acknowledgement for the excellent scientific work that has been done in the past 10 years.”
About MorphoMed
MorphoMed is a MedTech Start-Up company founded in Vienna in May 2017 focused on the development of new regenerative implants based on its proprietary medical silk technology. Silk can be completely cleaned from its antigenic sericin layer even in complex textile structures such as a braided ACL (anterior cruciate ligament). MorphoMed's lead product RegACL is a regenerative medical silk ACL implant potentially helping thousands of patients after an ACL rupture. Patients can get back to their normal life including sports activities only weeks after surgery. Furthermore; full regeneration of their body’s own natural ligaments is expected over the years and has been successfully demonstrated in a sheep model.
MorphoMed is a spin-off of the Ludwig Boltzmann Institute for Experimental and Clinical Traumatology in the AUVA Trauma Research Center as well as an associate member of the Austrian Cluster for Tissue Regeneration.
Contact
Dr. Michael Jakusch, CEO
MorphoMed GmbH
office@morphomed.at
www.morphomed.at
MorphoMed wins “Medtech Award” of aws Best of Biotech competition
Out of a total of 30 submitted projects, MorphoMed was awarded the Medtech prize by the Ministry of Science, Research and Economy in the 2017 Best of Biotech business plan competition organized by Austria Wirtschaftsservice GmbH (aws). MorphoMed had submitted its business plan regarding the development and commercialization of a new, regenerative anterior cruciate ligament implant from medical grade silk.
During the award ceremony in Palais Ferstl the representative of the Jury, Dr. Angelika Weinländer-Mölders explained that MorphoMed's business plan was awarded because of the evident medical need, the clear development strategy and the experienced management team that combines all necessary competences to realize the presented business plan.
LISA Vienna has donated the prize of 10,000.- Euro and the “Golden Viennese Heart”, a special trophy created for the Medtech award. The MorphoMed team had the pleasure to receive this trophy from Dr. Peter Halwachs, one of the managing directors of LISA Vienna.
“We are very happy about the decision of the Jury and the award” says Bernhard Küenburg, CEO of MorphoMed. “The Medtech award is a great motivation for the entire team to continue its efforts to develop this product, which is a perfect example for regenerative medicine”. Prof. Heinz Redl, head of MorphoMed's scientific board adds: “We feel very honored and it is also an acknowledgement for the excellent scientific work that has been done in the past 10 years.”
About MorphoMed
MorphoMed is a MedTech Start-Up company founded in Vienna in May 2017 focused on the development of new regenerative implants based on its proprietary medical silk technology. Silk can be completely cleaned from its antigenic sericin layer even in complex textile structures such as a braided ACL (anterior cruciate ligament). MorphoMed's lead product RegACL is a regenerative medical silk ACL implant potentially helping thousands of patients after an ACL rupture. Patients can get back to their normal life including sports activities only weeks after surgery. Furthermore; full regeneration of their body’s own natural ligaments is expected over the years and has been successfully demonstrated in a sheep model.
MorphoMed is a spin-off of the Ludwig Boltzmann Institute for Experimental and Clinical Traumatology in the AUVA Trauma Research Center as well as an associate member of the Austrian Cluster for Tissue Regeneration.
Contact
Dr. Michael Jakusch, CEO
MorphoMed GmbH
office@morphomed.at
www.morphomed.at
copyright © vogus